≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat
    ≥99% Purity Verified by Third-Party Labs
    Free Shipping on Orders Over $100
    HPLC & Mass Spec 2X Tested
    Same Day Shipping on Orders Before 2PM EST Mon-Sat

    Research use only · Not for human or veterinary use

    α
    ALPHA CARBON LABS
    Metabolic
    8/17/2026

    5-Amino-1MQ and NNMT Inhibition in Adipocyte Hyperplasia Research

    A laboratory-focused overview of 5-Amino-1MQ and NNMT, distinguishing adipocyte differentiation, hyperplasia, and hypertrophy across experimental evidence types.

    Reviewed by Dr. Sarah ChenLast updated September 24, 2026

    5-Amino-1MQ and NNMT Inhibition in Adipocyte Hyperplasia Research

    5-Amino-1MQ is a small-molecule NNMT inhibitor studied in experimental systems relevant to adipocyte biology. Interpreting this literature requires separating enzyme inhibition, cellular differentiation, lipid accumulation, and changes in tissue cellularity. These are related research questions, but they are not interchangeable endpoints.

    Chemical Identity and Research Scope

    5-Amino-1MQ refers to 5-amino-1-methylquinolinium, a small molecule rather than a peptide. The quinolinium name identifies a cation; the counterion and complete material composition must be established from the documentation for the specific material. The supplied article does not establish a salt form, molecular formula, molecular weight, or numerical analytical specification for the material sold.

    The 5-Amino-1MQ material listing is separate from the published studies discussed here. A shared compound name does not establish that a commercial lot matches the material used in a publication or will reproduce its results.

    Nicotinamide N-methyltransferase, abbreviated NNMT, catalyzes methyl transfer from S-adenosylmethionine to nicotinamide, producing 1-methylnicotinamide and S-adenosylhomocysteine. Nicotinamide also participates in the salvage pathway that generates NAD+. NNMT therefore connects nicotinamide utilization with methyl-donor metabolism; it does not directly consume NAD+.

    This biochemical relationship does not mean that inhibiting NNMT necessarily increases NAD+ in every experimental system. Substrate availability, competing pathways, cell type, and sampling time all matter when interpreting metabolite measurements. The NAD+ material listing concerns a separate material and is not evidence for a combination effect with 5-Amino-1MQ.

    In biochemical assays and cultured adipocyte experiments, Neelakantan and colleagues (2017) investigated small-molecule NNMT inhibitors and cellular metabolic responses.[2] Enzyme-assay inhibition and cellular metabolite changes represent different levels of evidence. Neither alone establishes a change in adipocyte number within intact tissue.

    Hyperplasia, Hypertrophy, and Differentiation Are Different Endpoints

    Adipocyte hypertrophy

    Hypertrophy describes enlargement of existing adipocytes. Cell-size measurements and lipid-droplet measurements can help characterize this process, but total lipid content is not a direct measure of individual cell size.

    Adipocyte hyperplasia

    Hyperplasia describes an increase in adipocyte number. Establishing it requires evidence about cellularity, not merely a change in tissue mass, lipid staining, or expression of a differentiation marker. A study of hyperplasia should distinguish precursor proliferation, differentiation, and cell loss.

    Adipogenic differentiation

    Differentiation is the transition of precursor cells toward an adipocyte phenotype. In the mouse-derived 3T3-L1 cell model, Gao and colleagues (2015) reported that NNMT promoted adipogenic differentiation.[7] This in-vitro finding concerns a defined cell model. It does not establish that 5-Amino-1MQ prevents adipocyte hyperplasia in an organism, nor does it demonstrate a response to an Alpha Carbon Labs material.

    Reduced lipid staining in a culture can reflect several possibilities, including altered lipid metabolism, fewer viable cells, or a change in differentiation. Describing such a result as prevention of new adipocyte formation requires additional evidence that distinguishes these explanations.

    Separating the Evidence by Experimental Model

    Evidence types relevant to interpreting NNMT research
    Evidence typeResearch questionInterpretive boundary
    Biochemical assaysDoes a compound inhibit NNMT activity under defined assay conditions?An enzyme result does not establish cellular exposure, selectivity across other targets, or tissue effects.
    In-vitro cell modelsHow do NNMT perturbations relate to differentiation, metabolites, or lipid accumulation?Culture conditions and cell identity constrain interpretation; viability and cell number can confound aggregate measurements.
    Animal modelsHow does NNMT perturbation relate to tissue-level measurements in a defined organism?Species, tissue, genetic background, and study design limit extrapolation.
    Human observational studiesIs NNMT expression or activity associated with measured tissue or metabolic characteristics?Association does not establish causation or a response to an NNMT inhibitor.
    In-silico analysesWhat molecular interactions or pathway relationships are predicted?Predictions require experimental validation. No computational result is used here to establish 5-Amino-1MQ activity.

    In mouse experiments, Kraus and colleagues (2014) investigated NNMT knockdown in relation to adipose and metabolic measurements.[1] Genetic knockdown changes enzyme abundance and is not equivalent to small-molecule inhibition. Results from that animal model do not establish the activity of 5-Amino-1MQ in a different model or the performance of a supplier's material.

    Human adipose-tissue research, including the study by Riederer and colleagues (2009), provides a distinct context for examining NNMT.[4] Measurements in human tissue must not be presented as evidence that administering an NNMT inhibitor produces a particular outcome. They also do not establish the direction of causality between NNMT and adipose characteristics.

    The attached bibliography also includes work on other tissues and broader reviews. Those references are not substitutes for direct measurements of adipocyte number in an explicitly identified experimental model.

    Designing Interpretable Laboratory Experiments

    The following considerations are experimental-design recommendations, not a reproduction of a cited protocol. Exact methods should be selected and documented for the laboratory's model and analytical question.

    • Define the primary endpoint. Specify whether the experiment concerns NNMT activity, differentiation, cell number, cell size, lipid accumulation, or metabolite abundance.
    • Document the biological system. Record cell identity, differentiation state, passage information where relevant, and culture conditions.
    • Separate target measurements from downstream responses. Measure NNMT activity or another justified target-engagement endpoint rather than inferring inhibition solely from lipid staining.
    • Control for cell number and viability. Interpret bulk lipid and metabolite measurements alongside appropriate cellular measurements.
    • Use complementary endpoints. Pair morphology with suitable molecular or functional measurements when assessing differentiation. Do not treat a single marker as proof of hyperplasia.
    • Measure the relevant metabolites. If the hypothesis concerns NAD+ salvage or methyl-donor metabolism, collect appropriate analytical data rather than assuming a pathway response from the inhibitor label.
    • Include suitable controls. Vehicle controls, assay blanks, and independent approaches to perturbing NNMT can help distinguish biological effects from assay interference or unrelated compound effects.
    • Report uncertainty. Document replication, normalization, variability, and the limits of the assay before drawing a mechanistic conclusion.

    A change in an endpoint should be reported at the level actually measured. For example, lower culture lipid content is not synonymous with fewer adipocytes, and increased NAD+ abundance is not by itself a measure of metabolic flux.

    Material Documentation and Laboratory Handling

    Reproducibility depends on identifying the material used in each experiment. Review available lot-specific records for identity, counterion, assay results, analytical methods, and relevant impurities. Chromatographic purity, chemical identity, and concentration are distinct attributes; a single reported purity value does not establish all three.

    Alpha Carbon Labs provides internal pages for quality-control information and Certificates of Analysis. These are documentation resources, not evidence that every lot has a particular test result or that a material is equivalent to a published study reagent. Any analytical claim should be limited to the actual lot, method, and result documented.

    The source article supplies no validated storage conditions, stability data, or compound-specific hazard classification. Do not infer these from a compound's experimental use. Consult the applicable safety data sheet, supplier documentation, and institutional chemical-risk assessment for handling, protective equipment, storage, and disposal. An absence of reported hazards is not evidence of an absence of risk.

    Research Interpretation: Common Questions

    Does NNMT inhibition demonstrate reduced adipocyte hyperplasia?

    No. Enzyme inhibition is a mechanistic measurement; hyperplasia is a cell-number outcome. Connecting them requires direct evidence in the same experimental system and consideration of differentiation, proliferation, and cell loss.

    Can genetic NNMT studies be treated as 5-Amino-1MQ studies?

    No. Genetic perturbation and pharmacological inhibition differ in mechanism, extent, and timing. Agreement between independent approaches can support an interpretation, but the approaches are not interchangeable.

    Does a change in NAD+ establish the proposed mechanism?

    Not by itself. Metabolite abundance can change for multiple reasons. Supporting measurements and appropriate controls are needed to connect NNMT inhibition to a particular pathway response.

    Do published results establish commercial-lot performance?

    No. Literature findings apply to the material, model, and conditions actually studied. Lot-specific analytical documentation and experimental validation are needed for the material used in a new investigation.

    References

    1. Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., ... & Kahn, B. B. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262. — https://pubmed.ncbi.nlm.nih.gov/24717514/
    2. Neelakantan, H., Vance, V., Wang, H. L., McHardy, S. F., & Watowich, S. J. (2017). Noncompetitive small molecule inhibitors of nicotinamide N-methyltransferase alter cellular metabolism and increase energy expenditure. Biochemical Pharmacology, 142, 60-71. — https://pubmed.ncbi.nlm.nih.gov/28739202/
    3. Stromsdorfer, K. L., Yamaguchi, S., Yoon, M. J., Moseley, A. C., Franczyk, M. P., Kelly, S. C., ... & Yoshino, J. (2016). Targeted deletion of nicotinamide N-methyltransferase attenuates diet-induced unhealthful aging. Cell Reports, 16(9), 2353-2362. — https://pubmed.ncbi.nlm.nih.gov/27568565/
    4. Riederer, M., Haas, J., Eberl, H., Bohlender, J. M., & Kientsch-Engel, R. (2009). Nicotinamide N-methyltransferase in human adipose tissue. Atherosclerosis, 204(2), 412-417. — https://pubmed.ncbi.nlm.nih.gov/18995856/
    5. Kannt, A., Pfenninger, A., Teichert, L., Tönjes, A., Dietrich, A., Schön, M. R., ... & Blüher, M. (2018). Association of nicotinamide-N-methyltransferase with metabolic syndrome. Endocrine Connections, 7(3), 441-450. — https://pubmed.ncbi.nlm.nih.gov/29419409/
    6. Campagna, R., Salvucci, A., & Pozzi, V. (2021). Nicotinamide N-Methyltransferase: A Potential Target for Obesity and Metabolic Syndrome. International Journal of Molecular Sciences, 22(22), 12151. — https://pubmed.ncbi.nlm.nih.gov/34830030/
    7. Gao, Y., Shen, C. H., Lin, E. Z., & Wang, Y. (2015). Nicotinamide N-methyltransferase promotes the differentiation of 3T3-L1 cells into adipocytes. International Journal of Clinical and Experimental Pathology, 8(8), 9114-9121. — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4583906/
    8. Hong, S., Moreno-Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Hwang, D., ... & Kahn, B. B. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 21(8), 887-894. — https://pubmed.ncbi.nlm.nih.gov/26168282/
    9. Bratu, O. G., Spinu, D., Marcu, D., & Mischianu, D. (2020). Nicotinamide N-methyltransferase: An emerging player in energy metabolism and longevity. Ageing Research Reviews, 62, 101099. — https://pubmed.ncbi.nlm.nih.gov/32688009/
    10. Neelakantan, H., Brightwell, C. R., Graber, T. G., Maroto, R., Wang, H. L., McHardy, S. F., ... & Watowich, S. J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481-492. — https://pubmed.ncbi.nlm.nih.gov/30946853/

    Limitations: Findings are specific to the materials, models, and conditions studied. Published findings do not establish safety, effectiveness, approval, or suitability of the material sold by Alpha Carbon Labs for human or veterinary use. These materials are intended solely for nonclinical laboratory research.

    References

    1. 1. Kraus, D., Yang, Q., Kong, D., Banks, A. S., Zhang, L., Rodgers, J. T., ... & Kahn, B. B. (2014). Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature, 508(7495), 258-262.
    2. 2. Neelakantan, H., Vance, V., Wang, H. L., McHardy, S. F., & Watowich, S. J. (2017). Noncompetitive small molecule inhibitors of nicotinamide N-methyltransferase alter cellular metabolism and increase energy expenditure. Biochemical Pharmacology, 142, 60-71.
    3. 3. Stromsdorfer, K. L., Yamaguchi, S., Yoon, M. J., Moseley, A. C., Franczyk, M. P., Kelly, S. C., ... & Yoshino, J. (2016). Targeted deletion of nicotinamide N-methyltransferase attenuates diet-induced unhealthful aging. Cell Reports, 16(9), 2353-2362.
    4. 4. Riederer, M., Haas, J., Eberl, H., Bohlender, J. M., & Kientsch-Engel, R. (2009). Nicotinamide N-methyltransferase in human adipose tissue. Atherosclerosis, 204(2), 412-417.
    5. 5. Kannt, A., Pfenninger, A., Teichert, L., Tönjes, A., Dietrich, A., Schön, M. R., ... & Blüher, M. (2018). Association of nicotinamide-N-methyltransferase with metabolic syndrome. Endocrine Connections, 7(3), 441-450.
    6. 6. Campagna, R., Salvucci, A., & Pozzi, V. (2021). Nicotinamide N-Methyltransferase: A Potential Target for Obesity and Metabolic Syndrome. International Journal of Molecular Sciences, 22(22), 12151.
    7. 7. Gao, Y., Shen, C. H., Lin, E. Z., & Wang, Y. (2015). Nicotinamide N-methyltransferase promotes the differentiation of 3T3-L1 cells into adipocytes. International Journal of Clinical and Experimental Pathology, 8(8), 9114-9121.
    8. 8. Hong, S., Moreno-Navarrete, J. M., Wei, X., Kikukawa, Y., Tzameli, I., Hwang, D., ... & Kahn, B. B. (2015). Nicotinamide N-methyltransferase regulates hepatic nutrient metabolism through Sirt1 protein stabilization. Nature Medicine, 21(8), 887-894.
    9. 9. Bratu, O. G., Spinu, D., Marcu, D., & Mischianu, D. (2020). Nicotinamide N-methyltransferase: An emerging player in energy metabolism and longevity. Ageing Research Reviews, 62, 101099.
    10. 10. Neelakantan, H., Brightwell, C. R., Graber, T. G., Maroto, R., Wang, H. L., McHardy, S. F., ... & Watowich, S. J. (2019). Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology, 163, 481-492.

    Related Metabolic research

    All research information is for educational purposes only. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.